ubrelvy
Treatment for Cluster Headache
Ubrelvy (ubrogepant) is a selective calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP-mediated neurogenic inflammation in cluster headache pathogenesis. By inhibiting the CGRP receptor, it reduces pain signaling and vascular dilation associated with cluster headache attacks. The medication provides acute treatment by rapidly alleviating headache symptoms and potentially shortening the duration and intensity of cluster headache episodes.
1579
REPORTED SIDE EFFECTS